Edition:
United States

Almirall SA (ALM.MC)

ALM.MC on Madrid SE C.A.T.S.

15.33EUR
26 May 2017
Change (% chg)

-- (--)
Prev Close
€15.33
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
182,868
52-wk High
€16.88
52-wk Low
€12.13

Latest Key Developments (Source: Significant Developments)

Almirall Q1 net profit down at 19.6 mln euros
Monday, 8 May 2017 02:00am EDT 

May 8 (Reuters) - ALMIRALL SA ::Q1 EBITDA 55.0 MILLION EUROS ($60.4 MILLION) VERSUS 54.8 MILLION EUROS YEAR AGO.Q1 NET PROFIT 19.6 MILLION EUROS VERSUS 21.7 MILLION EUROS YEAR AGO.Q1 REVENUE UP 5 PERCENT AT 210.7 MILLION EUROS VERSUS 201.0 MILLION EUROS YEAR AGO.Q1 RESEARCH AND DEVELOPMENT EXPENSES UP 26 PERCENT AT 24.2 MILLION EUROS VERSUS 19.2 MILLION EUROS YEAR AGO.SEES ITS SKILARENCE DRUG FOR PSORIASIS TO REACH PEAK SALES OF OVER 50 MILLION EUROS.SEES TO START SELLING SKILARENCE IN EUROPE IN Q3 2017.SEES TO LAUNCH TILDRAKIZUMAB IN 2018 WITH PEAK SALES OF OVER 200 MILLION EUROS.CONFIRMS FY 2017 EBITDA AND REVENUE GUIDANCE.  Full Article

Almirall gets positive CHMP opinion for drug to treat psoriasis
Friday, 21 Apr 2017 06:42am EDT 

April 21 (Reuters) - Almirall SA ::Receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for dimethyl fumarate for the treatment of patients with moderate-to-severe chronic plaque psoriasis.  Full Article

Almirall signs revolving credit facility deal for 250 mln euros
Tuesday, 4 Apr 2017 01:56am EDT 

Almirall SA : Says 4.625 percent senior notes due 2021 have been redeemed .Enters into a revolving credit facility agreement for a maximum amount of 250 million euros ($266.5 million) over a four year period with an average interest rate lower than 1 percent.  Full Article

Almirall says regulatory filing for Tildrakizumab in Europe is validated
Friday, 24 Mar 2017 02:57am EDT 

Almirall SA :The company and Sun Pharma announce validation of regulatory filing for Tildrakizumab, an antibody designed for treatment of moderate-to-severe plaque psoriasis, by the European Medicines Agency (EMA).  Full Article

Sun Pharma says filing of tildrakizumab with European Medicines Agency by Almirall
Friday, 24 Mar 2017 12:53am EDT 

Sun Pharmaceutical Industries Ltd : Says validation of regulatory filing of tildrakizumab with the european medicines agency (EMA) by Almirall. . Tildrakizumab is an investigational IL-23P19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis. .Filing includes efficacy, safety data from pivotal phase III clinical trials that included over 1,800 patients.  Full Article

Almirall appoints new chief scientific officer
Friday, 17 Mar 2017 03:16am EDT 

Almirall SA :Appoints dermatologist Bhushan Hardas as chief scientific officer and executive vice president research and development, starting in April 2017.  Full Article

Astrazeneca signs deal with Circassia over Almirall's products
Friday, 17 Mar 2017 03:13am EDT 

Almirall SA : Astrazeneca enters into a strategic collaboration with Circassia for the development and commercialization of Tudorza and Duaklir in the United States [nFWN1GT0XB] . Says Tudorza, Duaklir are products licensed by Almirall to Astrazeneca in an agreement from July 30, 2014 .Under terms of collaboration, Circassia will lead promotion of Tudorza in the US and has been granted an option to gain full commercial rights in the future.  Full Article

Almirall and Symatese enter into collaboration for development of aesthetics products
Thursday, 16 Mar 2017 02:56am EDT 

Almirall SA : Almirall and Symatese enter into a global strategic collaboration for development and commercialization of products in the aesthetics field . Symatese grants Almirall exclusive license for commercialization of hyaluronic acid facial fillers worldwide in exchange of upfront payment of 7.5 million euros ($8.0 million) and subsequent event milestones, royalties and sales milestones .This agreement reinforces Almirall's strategy to continue building a presence in aesthetic medicine.  Full Article

Almirall presents new data from Tildrakizumab clinical development program
Tuesday, 7 Mar 2017 11:32am EST 

Almirall SA : Says presented new analyses of phase 1 and pivotal phase 3 clinical trials of Tildrakizumab, an inhibitor IL-23p19 which is currently being evaluated in patients with moderate-to-severe plaque psoriasis, during an annual meeting of American Academy of Dermatology .Says data from clinical trials demonstrates long-term efficacy of Tildrakizumab.  Full Article

Almirall to amortize senior bonds due 2021, signs revolving credit facility
Monday, 27 Feb 2017 02:59am EST 

Almirall SA : To amortize senior 4.625 percent bonds issued on March 27, 2014 in the amount of 324 million euros ($342.5 million) and maturing in 2021 .Says signs revolving credit facility for up to 250 million euros, over a period of 4 years, with an average interest of less than 1 percent.  Full Article

More From Around the Web

BRIEF-Almirall Q1 net profit down at 19.6 mln euros

* Q1 EBITDA 55.0 MILLION EUROS ($60.4 MILLION) VERSUS 54.8 MILLION EUROS YEAR AGO